DBV Technologies reported 5.28M in Selling and Administration Expenses for its second fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Selling And Administration Expenses Change
DBV Technologies DBVT:US 5.28M 1.22M
Acadia Pharmaceuticals ACAD:US $ 89.9M 6.78M
Alnylam Pharmaceuticals ALNY:US $ 169.98M 15.51M
Amarin AMRN:US 86.89M 3.75M
Biocryst Pharmaceuticals BCRX:US $ 38.02M 3.74M
Biomarin Pharmaceutical BMRN:US $ 196.83M 2.22M
Eleven Biotherapeutics EBIO:US 8.98M 379K
Esperion Therapeutics ESPR:US $ 29.61M 772K
Galectin Therapeutics GALT:US $ 1.88M 308K
Halozyme Therapeutics HALO:US $ 57.48M 43.64M
Insmed INSM:US $ 59.97M 3.23M
Intercept Pharmaceuticals ICPT:US $ 39.98M 10.02M
IONIS PHARMACEUT IONS:US $ 33.8M 325K
Neurocrine Biosciences NBIX:US $ 182.8M 17.9M
Ptc Therapeutics PTCT:US $ 79.89M 6.62M
Sarepta Therapeutics SRPT:US $ 154.32M 82.48M
Ultragenyx Pharmaceutical RARE:US $ 68.14M 825K
United Therapeutics UTHR:US $ 141.5M 62.5M
YTE INCY:US $ 253.28M 43.69M